Novel treatments of depression: bridging the gap in current therapeutic approaches
Exploration of Neuroscience August 5, 2024 DOI: 10.37349/en.2024.00049 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Narrative review Peer reviewed |
|---|---|
| Topics | Depression Psychedelic-assisted therapy |
| Keywords | Glutamatergic modulation Brain stimulation Anti-inflammatory agents Gut-brain axis Gaba modulation Depression: depression Treatments Therapies Diverse strategies Beyond conventional methods New therapeutic approaches Significant hope |
| Citations | 6 |
| Key findings | Novel treatments targeting glutamatergic modulation, brain stimulation, anti-inflammatory agents, gut-brain axis, GABA modulation, and psychedelic-assisted therapy may help address therapeutic gaps in depression management. |
Abstract
Depression poses a significant global health burden, yet current therapeutic approaches focusing on monoaminergic neurotransmission often fall short of achieving full remission and managing acute episodes effectively. This article explores novel treatment avenues beyond conventional monoaminergic approaches, focusing on emerging strategies targeting glutamatergic modulation, electrophysiological/magnetic brain stimulation techniques, anti-inflammatory agents, gut-brain axis interventions, gamma-aminobutyric acid (GABA) modulation, and psychedelic-assisted therapy. Through a narrative review of recent literature, this paper elucidates the mechanisms, clinical efficacy, safety profiles, and future directions of these innovative treatments. These insights offer valuable perspectives for advancing depression management and bridging existing therapeutic gaps.